Health Canada experiences with early identification of potential carcinogens - An Existing Substances Perspective Sunil Kulkarni Hazard Methodology Division,

Slides:



Advertisements
Similar presentations
March, 2009 An Overview of the Chemicals Management Plan.
Advertisements

ComET Peer Input Meeting Context & Objectives Nov. 8th, 2004 B ette Meek, Health Canada
UNEP Advisory Group Meeting Geneva, Switzerland December 12, 2014
Evaluation of a potential mutagenic MOA based on analysis of the weight of evidence and using the modified Hill criteria Martha M. Moore, Ph.D. Director,
1 High Production Volume (HPV) Challenge Program Diane Sheridan Chief, Existing Chemicals Branch, Chemical Control Division, Office of Pollution Prevention.
Nonclinical Pharmacology/ Toxicology Data for PROTOPIC  (Tacrolimus ointment for Atopic Dermatitis) Barbara Hill, Ph.D. Division of Dermatologic and Dental.
1 High Production Volume (HPV) Challenge Program – Future Directions Jim Willis Director, Chemical Control Division, Office of Pollution Prevention and.
Chemical Carcinogens – workplace risk assessment and health surveillance Tiina Santonen Paide.
June 2010 LANDSIEDEL 1 Chemical Industries Role in Tomorrows Toxicity Testing Robert Landsiedel, Susanne Kolle, Tzutzuy Ramirez, Hennicke Kamp and Ben.
Development of an Institutional Knowledge-base at FDA’s Center for Food Safety and Applied Nutrition Kirk B. Arvidson 1, Annette McCarthy 1, Chihae Yang.
Priority-setting for the Endocrine Disruptor Screening Program: Pesticide Active Ingredients Penelope A. Fenner-Crisp Office of Pesticide Programs U.S.
National Pesticide Program A New Toxicology Testing Paradigm: Meeting Common Needs Steven Bradbury, Director Environmental Fate and Effects Division Office.
McKim Workshop on Strategic Approaches for Reducing Data Redundancy in Cancer Assessment Jay R. Niemelä Technical University of Denmark National Food Institute.
1 Development & Evaluation of Ecotoxicity Predictive Tools EPA Development Team Regional Stakeholder Meetings January 11-22, 2010.
Canada’s approach to Chemicals Management under the CMP – Domestic Update CEC SMOC Public Session San Antonio April 1&2, 2009.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Discovering Substructures in Chemical Toxicity Domain Masters Project Defense by Ravindra Nath Chittimoori Committee: DR. Lawrence B. Holder, DR. Diane.
What Do Toxicologists Do?
Value of in vitro assays in your REACH dossier Frédérique van Acker 18 November 2014.
June 16-19, USEPA Cancer Guidelines: Mode of Carcinogenic Action 1 ICABR – Impacts of the Bioeconomy on Agricultural Sustainability, the Environment.
Criteria for Screens— Review of the EDSTAC Recommendations Presentation to the EDMVS July 23, 2002.
Application of Toxicology Databases in Drug Development (Estimating potential toxicity) Joseph F. Contrera, Ph.D. Director, Regulatory Research and Analysis.
Health and Safety Executive UK Approach to Risk Assessment of Genotoxic Carcinogens in the Occupational Setting Dr Susy Brescia Chemicals Regulation Directorate.
Results of Canadian DSL Categorization Activities – What’s Next CPPI April 28, 2006 Calgary AB Health Santé Canada.
1 Discussion of the 2006 Inventory Update Reporting Data December 12, 2006 Nhan Nguyen U.S. EPA.
Committee on Carcinogenicity (COC) Approach to Risk Assessment of Genotoxic Carcinogens David H. Phillips* COC Chairman Descriptive vs. Quantitative.
Dr. Manfred Wentz Director, Hohenstein Institutes (USA) Head, Oeko-Tex Certification Body (USA) AAFA – Environmental Committee Meeting November 10, 2008.
HERA at CED XXXI C.Lally 1 Human & Environmental Risk Assessment Human Health Risk Assessment under HERA: Challenges and Solutions Christeine Lally Co-Chair.
International Initiatives and the U.S. HPV Challenge Program Ken Geiser, PhD Lowell Center for Sustainable Production University of Massachusetts Lowell.
Results of Categorization and Next Steps George Enei Director, Existing Substances Division May, 2006.
Chad B. Sandusky, Ph.D. Physicians Committee for Responsible Medicine, Washington DC, USA STRATEGIES TO REDUCE ANIMAL TESTING IN US EPA’S HIGH PRODUCTION.
Mike Comber Consulting TIMES-SS Assessment of skin sensitisation hazard Presented on behalf of the TIMES-SS consortia.
1 Tier 1 EDSP: Other Scientifically Relevant Information Barbara Neal Exponent December 13, 2010.
Identifying Tools to Rapidly Characterize & Prioritize Chemicals in Commerce for Prevention Joel A. Tickner, ScD Lowell Center for Sustainable Production.
2 n McKim Workshop on Reducing Data Redundancy in Cancer Assessment | 8 – 10 May 2012 | Baltimore, MD Highlighting the Need for AOPs in Streamlining Hazard.
Risk Assessment Nov 7, 2008 Timbrell 3 rd Edn pp Casarett & Doull 7 th Edn Chapter 7 (pp )
1 Canadian Environmental Protection Act, 1999 Update on Preparations for the CEPA 1999 Parliamentary Review September, 2005 Presentation to the Canadian.
Juan Alguacil, MD Huelva University Brussels, 26 June 2012 Limits on Occupational Exposure Limits for Carcinogens 8th Seminar on workers’ protection &
Mike Comber TIMES-SS Application of Reactivity Principles in Screening for Skin Sensitisers Presented on behalf of the TIMES-SS consortia & International.
Background on Furan in Foods Nega Beru, Ph.D. Director, Division of Plant Product Safety Office of Plant and Dairy Foods Center for Food and Applied Nutrition.
EDSP: T IER 1 T ESTING I NFORMATION C OLLECTION ISRTP 2010 Endocrine Workshop EDSP Compliance December 13, 2010 Susan Ferenc, DVM, Ph.D.
HC Screening State of the Science Reports Update to the ICG February 14th/05 Presented by: Bette Meek Existing Substances Division Health Canada.
McKim Conference on Predictive Toxicology
QSAR in CANCER ASSESSMENT PURPOSE and AGENDA Gilman Veith Duluth MN May 19-21, 2010.
An Overview of the Objectives, Approach, and Components of ComET™ Mr. Paul Price The LifeLine Group All slides and material Copyright protected.
OECD’s work on Adverse outcome pathways
Barcelona April, 2008 Overview of the QSAR Application Toolbox Gilman Veith International QSAR Foundation Duluth, Minnesota.
Prioritization Process and Development of the Hazard Characterization Documents Office of Pollution Prevention and Toxics U.S. Environmental Protection.
1/29/ Geoff Granville n Background: Ü Confusion within industry (and the public) about the meaning of DSL, NSN, PSL, CSDSL, Schedule 1, etc Ü Issues.
McKim Workshop on Strategic Approaches for Reducing Data Redundancy in Cancer Assessment Duluth, MN, USA 19 May, 2010.
The Future of Chemical Toxicity Testing in the U.S.
Pediatric Subcommittee of the AIDAC October 29-30, Topical Immunosuppressants (Calcineurin Inhibitors) - Animal Toxicology October 30, 2003 Barbara.
QSAR in CANCER ASSESSMENT PURPOSE and AGENDA Gilman Veith Duluth MN May 19-21, 2010.
Toxic effects Acute / chronic Reversible / irreversible Immediate / delayed Idiosyncratic - hypersensitivity Local / systemic Target organs.
Responsible Officer, Volume 112 Monographs Programme
James G. Farrelly, Ph.D. Pharmacology Team Leader Division of Antiviral Drug Products Center for Drug Evaluation and Research Food and Drug Administration.
Abstract A step-wise or ‘tiered’ approach has been used as a rational procedure to conduct environmental risk assessments in many disciplines. The Technical.
General Concepts in QSAR for Using the QSAR Application Toolbox
QSAR Application Toolbox: Step 12: Building a QSAR model
FIFRA SAP Meeting February 2, 2010
General Concepts in QSAR for Using the QSAR Application Toolbox
Making it more relevant! Higher-tier data and Weight of Evidence Day 2. Adam Peters and Graham Merrington 2017.
Decision Contexts in a Changing Toxicology Paradigm
Categorization of the Canadian Domestic Substances List
Canada’s Chemical Management Plan – post categorization of the DSL
Ovanes Mekenyan, Milen Todorov, Ksenia Gerova
International Initiatives and the U.S. HPV Challenge Program
The Category Approach for Predicting Mutagenicity and Carcinogenicity
EFSA’s Chemical Hazards Database
Presentation transcript:

Health Canada experiences with early identification of potential carcinogens - An Existing Substances Perspective Sunil Kulkarni Hazard Methodology Division, Existing Substances Risk Assessment Bureau Health Canada, Ottawa, ON

Outline Brief introduction DSL - Categorization – Tools/Approaches Chemicals Management Plan – Phase I & II Remaining priorities (Q)SAR tools we use Challenges of (Q)SAR models & modelable endpoints (Q)SAR results/analyses

Existing Substances under CEPA 1999 Approximately 23,000 substances (e.g., industrial chemicals) on the Domestic Substances List (DSL) Includes substances used for commercial manufacturing or manufactured or imported in Canada at >100 kg/year between Jan 1, 1984 and Dec 31, 1986

Categorization Identify substances on the basis of exposure or hazard to consider further for screening assessment and to determine if they pose “harm to human health” or not A variety of tools including those based on (Q)SAR approaches were applied

~3200 remaining priorities Categorization 23,000 DSL chemicals 4,300 priorities Chemicals Management Plan

Chemicals Management Plan (CMP) To assess and manage the risks associated with 4300 legacy substances identified through categorization by substances were prioritized into high (~500), medium (~3200) and low concern substances (~550) CMP brings all existing federal programs together into a single strategy to ensure that chemicals are managed appropriately to prevent harm to Canadians and their environment It is science-based and specifically designed to protect human health and the environment through four major areas of action: Taking action on chemical substances of high concern Taking action on specific industry sectors Investing in research and biomonitoring Improving the information base for decision-making through mandatory submission of use and volume information

DSL Categorization Commercial (Q)SAR models; basis for decision making (prioritization) Commercial and some public domain (Q)SAR models, Metabolism, Analogue identification, Read-across; basis for decision making but mainly supportive evidence Ministerial Challenge Phase CMP (high priorities) CMP II (includes data poor substances) Commercial and public domain (Q)SAR models, Analogue identification, Chemical categories, Read-across, Metabolism, in-house models/tools Historical use of (Q)SAR applications

Universe of chemicals in work plan 4300 existing chemical substances to be addressed by 2020: ~1500 to be addressed by 2016 through the groupings initiative, rapid screening and other approaches

Remaining Priorities - Scope

(Q)SAR tools are generally only applicable to discrete organics!

Remaining Priorities – Data availability Are there enough data-rich analogues? (Q)SAR opportunities? 58% 4% 15% 23%

Approach

Human health risk assessment Chemical’s inherent toxicity & potential human exposure Assess a range of endpoints including genotoxicity, carcinogenicity, developmental toxicity, reproductive toxicity & skin sensitization (Q)SAR approaches, including analogue/chemical category read across are used to support our assessments (line of evidence) Apply weight of evidence and precaution in our decision-making

Hierarchical consideration of sources of information Chemical Hazard Assessment

Predictive tools for hazard assessment Commercial Casetox Topkat Derek Model Applier Oasis Times Non-commercial OECD QSAR Toolbox Toxtree OncoLogic Caesar (Vega) lazar Supporting tools Leadscope Hosted - chemical data miner Pipeline Pilot – cheminformatics and workflow builder

Identifying toxic potential Relevance to humans Essential to have a balanced judgement of the totality of available evidence Consider strengths & weaknesses of evidence Hazard assessment

Reliability of estimations Minimizing uncertainties and maximizing confidence in predictions considering multiple factors: - OECD QSAR Validation principles - accuracy of input - quality of underlying biological data - multiple models based on different predictive paradigms or methodologies - mechanistic understanding - inputs from in vitro/in vivo tests (if available) Professional judgement of expert(s)

(Q)SAR tools/approaches to identify potential genotoxic carcinogens QSAR Toolbox profiler flags- DNA/Protein binding, Benigni-Bossa, OncoLogic Metabolic simulators (Toolbox/TIMES) + DNA/Protein binding/Benigni-Bossa flags Combination of (Q)SAR models for genotoxicity & carcinogenicity (Casetox, Model Applier, Derek, Times, Toxtree, Caesar, Topkat) Genotox - Salmonella (Ames) models for different strains, Chrom ab, Micronuclei Ind, Mouse Lymphoma mut with metabolic activation Carcinogenicity – Male & female rats, mice, rodent

(Q)SAR tools/approaches to identify potential non-genotoxic carcinogens Flags from QSAR Toolbox profilers – Benigni-Bossa flags QSAR models based on in vitro Cell Transformation assays such as Syrian Hamster Embryo, BALB/c-3T3, C3H10T1/2 Expert rule based systems Derek and Toxtree

Holds potential to form part of hazard identification strategy

Helpful to have a better understanding of Cell Transformation information in mechanistic interpretation of (non-genotoxic) carcinogenicity

Domain of most (Q)SAR models Few or no robust (Q)SAR models Ashby (1992), Prediction of non-genotoxic carcinogenesis. Toxicology Letters, 64/65,

Few or no (Q)SAR models

Basis of non-empirical approaches PhysChemBio activityFunction ofAbility to model/ Use in decision-making SimpleMolecular structureGood Complex Molecular structure Mechanism Metabolism Multi-step Challenging (uncertainty ↑) Complex BA not easily translated/explainable in terms of simple molecular structure/fragments to enable building a robust QSAR For instance, a QSAR model for carcinogenicity only predicts Yes/No without any information about its mechanism Availability of data rich analogues is essential for read-across approaches

(Q)SAR analysis

Performance of some (Q)SAR models A set of chemicals with in vitro and in vivo data on genotoxicity and carcinogenicity was chosen Predictions were obtained for different human health relevant endpoints by running these through a variety of (Q)SAR models Performance of models to discriminate carcinogenic and non-carcinogenic chemicals was evaluated by analysing the results Structural analysis of chemicals incorrectly classified by all models revealed a diverse group of chemicals with few trends (we are working on that) Failure of models/expert systems to flag them as “Out of domain”

Prediction results/analysis Dataset of approx. 100 chemicals : Ames PN ratio=55:46 Carc PN ratio: 49: are positive in both Carc and Ames 20 are negative in both; 32 are only Ames positive 26 are Carc positive but Ames negative (non-Gtx Carc?)

Performance of QSAR models to discriminate carcinogenic/non-carcinogenic chemicals (n=100) Models Casetox 2.4 Model Applier 1.4 Topkat 6.2 Toxtree 2.5 SHE=Syrian Hamster Embryo model NgC=Non-genotoxic carcinogenicity a1 (96) a2 (98) b1 (73) c1 (68) b2 (76) c2 (29) SHE carc(68) d (37)

Performance of in vitro Cell Transformation QSAR models to discriminate carcinogenic/non- carcinogenic chemicals (n=130) Legend CTA=Cell Transformation assay based model SHE=Syrian Hamster Embryo BALB/c 3T3 C3H 10T1/2 CTA models exhibit potential but there is scope for improvement

Performance of some (Q)SAR models to identify non-genotoxic carcinogens Current cancer models aren’t designed to inform about genotoxic or non-genotoxic events in the carcinogenesis process SHE(31) a1(43) a2(44) c2 (10) b2(42) c1(33) b1(41) d1(6) e(20) d2(46)

Data analysis

Comparative ability of Ames & SHE tests to discriminate carcinogens/non-carcinogens SHE (150) SHE+Ames (70) Ames (700)

MN (190) CA (300) MLm (220) SHE (55) Performance of genotoxicity and CT tests to discriminate (Ames -) carcinogens/non-carcinogens Legend SHE=Syrian Hamster Embryo MLm=Mouse Lymphoma mutation CA=Chromosomal Aberration MN=Micronuclei induction

Performance of genotoxicity and CT tests to discriminate (Ames +) carcinogens/non-carcinogens

Ability of reprotoxicity data to discriminate carc/non-carc chemicals Legend FRR=female rat reproductive FRodR=female rodent repro MMR=male mice repro FMR=female mice repro MRodR=male rodent repro MRR=male rat repro

Current performance Scope for improvement Finally……….. fpr tpr

Examples from CMP I where (Q)SAR or analogue-read across approaches were used as supporting information n-butyl glycidyl ether (CAS ) MAPBAP acetate (CAS ) DAPEP (CAS ) Disperse Red 179 (CAS )